Body weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. The dose-normalized AUClast is not significantly different between the groups, suggesting that KR-33493 is governed by linear kinetics
Cell Experiment | |
---|---|
Cell lines | |
Preparation method | |
Concentrations | |
Incubation time |
Animal Experiment | |
---|---|
Animal models | specific pathogen-free rats |
Formulation | |
Dosages | 50, 150, and 500 mg/kg/day |
Administration | i.v. |
Molecular Weight | 460.34 |
Formula | C20H18BrN3O3S |
CAS Number | 1021497-97-1 |
Form | Solid |
Solubility (25°C) | 31 mg/mL in DMSO |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related TNF Receptor Products |
---|
Chilob7/4
Chilob7/4 is a chimeric agonist anti-CD40 IgG1 antibody that can be used for tumor-related studies. |
VIB4920
VIB4920 is a fusion protein that binds to CD40L on activated T cells and blocks the interaction of CD40L with CD40-expressing B cells and other possible binding substrates. |
ABBV-428
ABBV-428 is a bispecific antibody targeting CD40/Mesothelin and can be used in studies related to solid tumors. |
TNF-α (31-45), human
TNF-α (31-45), human is a potent NF-kB pathway activator. |
LEESGGGLVQPGGSMK
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.